
    
      In the double-blind main study subjects were dosed at Weeks 0, 2 and 4, with the primary
      outcome, clinical response, being assessed at Week 6. Subjects who showed clinical response
      at Week 6 were eligible to enter this open-label extension study. The first visit in this
      extension study was 2 weeks after Week 6, i.e., Week 8. Subjects in this extension study were
      dosed at Weeks 8, 12, 16, 20 and 24, with the primary outcome, clinical response, being
      assessed at Week 26. All week numbers quoted are relative to the start of the double-blind
      main study.
    
  